Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Milestone Scientific designs and commercializes computer-controlled injection technologies for dental and medical applications. The company operates two primary segments: Dental (instruments and handpieces) and Medical (CompuFlo Epidural System). The company is classified as a "smaller reporting company" and a "non-accelerated filer."
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Product Sales, Net | $2,841,038 | $5,003,071 | $4,555,886 |
| Gross Profit | $1,910,167 | $3,474,191 | $3,265,041 |
| Gross Margin | 67.2% | 69.4% | 71.7% |
| Net Loss | $(1,059,332) | $(1,899,185) | $(3,477,696) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) | $(0.04) |
| Cash and Cash Equivalents | $2,066,770 | $2,066,770 | $1,274,314 |
| Working Capital | $3,719,927 | $3,719,927 | $3,346,572 |
| Convertible Notes Payable | $465,982 | $465,982 | $800,000 |
Note: Working Capital calculated as Total Current Assets ($8,117,198) minus Total Current Liabilities ($4,397,271).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22.3% quarter-over-quarter (QoQ) and 9.8% year-over-year (YoY) for the six-month period. Dental revenue grew 19.3% QoQ, driven significantly by $498,000 in sales to China (compared to $0 in the prior quarter). Medical revenue surged 231.5% QoQ to $106,400.
- Operating Expenses: Total operating expenses decreased 4.2% QoQ and 20.5% YoY (six months). Significant reductions were seen in consulting/professional fees (down 44.7% YoY) and R&D expenses (down 98.4% YoY). However, stock-based compensation increased 59.1% QoQ.
- Profitability: The net loss narrowed significantly to $1.9 million for the six months ended June 30, 2026, compared to $3.5 million in the prior year period. The loss from operations improved by $1.6 million YoY.
- Liquidity: Cash balances increased by $954,000 during the six-month period, primarily due to a private placement financing in April 2026.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that recurring operating losses and negative cash flows raise "substantial doubt" about the company's ability to continue as a going concern. Continued operations depend on generating sufficient revenue and obtaining additional financing.
- Financing Activity: In April 2026, the company completed a private placement of 7.96 million units at $0.27 per unit, raising approximately $1.8 million in cash and reducing convertible note principal by $351,000. Warrants issued in this offering could provide up to $2.69 million in additional proceeds if fully exercised.
- Listing Compliance: The company is not in compliance with NYSE American listing standards regarding minimum stockholders' equity ($4 million required; company has ~$3.5 million). A compliance plan is in place, with a deadline of April 8, 2027, to avoid delisting.
- Key Risks:
- China Exposure: Dual exposure to China as both a manufacturing source and a sales market creates risks related to tariffs, trade tensions, and supply chain disruptions.
- Medical Adoption: Commercialization of the CompuFlo Epidural System remains in early stages, with a material allowance ($504,000) held against slow-moving medical inventory.
- Dilution: Significant dilution risk exists from the recent private placement, outstanding warrants, and convertible notes.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing beyond current cash reserves of ~$2.1 million given the substantial doubt disclosure.
- China Revenue Sustainability: Assess the durability of the $498,000 in China sales amidst ongoing U.S.-China trade tensions and tariff risks.
- NYSE American Compliance: Monitor progress toward meeting the $4 million stockholders' equity requirement by April 2027 to prevent delisting.
- Medical Inventory Valuation: Review the $504,000 allowance for slow-moving medical finished goods and the timeline for commercial adoption of the CompuFlo system.
- Dilution Impact: Calculate the potential dilution from the 7.96 million warrants issued in the April 2026 private placement and the remaining $466,000 in convertible notes.